 |
(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenyl acetate 9-cis-retinyl acetate (API) |
|---|---|
| Trade Name | |
| Orphan Indication | Leber congenital amaurosis |
| USA Market Approval | USA |
| USA Designation Date | 2010-12-02 00:00:00 |
| Sponsor | Novelion Therapeutics, Inc.;887 Great Northern Way - Suite 250, Vancouver, British Columbia;V5T 4T5 |
